Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
TRIN Pharma
Baar, Zug, Switzerlandtrinpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
TRIN Pharma is a Swiss clinical-stage biotechnology company focused on developing novel small molecule therapeutics for the treatment of cancer. The company's lead program, TRIN-271, is a first-in-class activator of the mitochondrial protease ClpP, designed to induce mitochondrial dysfunction and cell death in malignant cells. TRIN Pharma targets hematological malignancies, specifically acute myeloid leukemia (AML), as well as various solid tumors. By leveraging mitochondrial stress responses, the company aims to provide new treatment options for patients with difficult-to-treat cancers.
- Therapeutic areas
- HematologyOncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on TRIN Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRIN Pharma.